Researchers’ reanalysis questions mortality data in FOURIER trial

In research published in BMJ, Juan Erviti, James Wright, Ken Bassett and others stated that they observed some inconsistencies between the information in the Clinical Study Report and that in the 2017 primary trial results publication for the FOURIER trial of evolocumab. In that context, they "aimed to restore the mortality data in the FOURIER trial based on the information contained in the death narratives in the CSR." The researchers conclude that after readjudication, "deaths of cardiac origin were numerically higher in the evolocumab group than in the placebo group in the FOURIER trial, suggesting possible cardiac harm." Reference Link